Literature DB >> 33974093

Recent advances in liposome formulations for breast cancer therapeutics.

Biyao Yang1, Bo-Ping Song1,2, Shaina Shankar1,3, Anna Guller1,4, Wei Deng5.   

Abstract

Among many nanoparticle-based delivery platforms, liposomes have been particularly successful with many formulations passed into clinical applications. They are well-established and effective gene and/or drug delivery systems, widely used in cancer therapy including breast cancer. In this review we discuss liposome design with the targeting feature and triggering functions. We also summarise the recent progress (since 2014) in liposome-based therapeutics for breast cancer including chemotherapy and gene therapy. We finally identify some challenges on the liposome technology development for the future clinical translation.

Entities:  

Keywords:  Breast cancer; Cancer therapy; Liposomal delivery; Triggerable liposomes

Year:  2021        PMID: 33974093     DOI: 10.1007/s00018-021-03850-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  163 in total

Review 1.  Liposome-based drug co-delivery systems in cancer cells.

Authors:  Sepideh Zununi Vahed; Roya Salehi; Soodabeh Davaran; Simin Sharifi
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2016-11-23       Impact factor: 7.328

2.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Cardoso; N Harbeck; L Fallowfield; S Kyriakides; E Senkus
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

4.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.

Authors:  Ian F Tannock; Carol M Lee; Jonathon K Tunggal; David S M Cowan; Merrill J Egorin
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

Review 5.  Drug resistance and the solid tumor microenvironment.

Authors:  Olivier Trédan; Carlos M Galmarini; Krupa Patel; Ian F Tannock
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

6.  Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells.

Authors:  Wenying Huo; Guannan Zhao; Jinggang Yin; Xuan Ouyang; Yinan Wang; Chuanhe Yang; Baojing Wang; Peixin Dong; Zhixiang Wang; Hidemichi Watari; Edward Chaum; Lawrence M Pfeffer; Junming Yue
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

Review 7.  Metastatic and triple-negative breast cancer: challenges and treatment options.

Authors:  Sumayah Al-Mahmood; Justin Sapiezynski; Olga B Garbuzenko; Tamara Minko
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 8.  Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.

Authors:  Zuan-Fu Lim; Patrick C Ma
Journal:  J Hematol Oncol       Date:  2019-12-09       Impact factor: 17.388

Review 9.  Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.

Authors:  Haitao Yang; MariaLynn Jaeger; Averi Walker; Daniel Wei; Katie Leiker; Tao Weitao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

10.  Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components.

Authors:  Ignazio Maggio; Hidde A Zittersteijn; Qian Wang; Jin Liu; Josephine M Janssen; Ivan Toral Ojeda; Silvère M van der Maarel; Arjan C Lankester; Rob C Hoeben; Manuel A F V Gonçalves
Journal:  Gene Ther       Date:  2020-01-03       Impact factor: 5.250

View more
  5 in total

1.  Metastasis suppressor NME1 in exosomes or liposomes conveys motility and migration inhibition in breast cancer model systems.

Authors:  Imran Khan; Brunilde Gril; Ayuko Hoshino; Howard H Yang; Maxwell P Lee; Simone Difilippantonio; David C Lyden; Patricia S Steeg
Journal:  Clin Exp Metastasis       Date:  2022-08-08       Impact factor: 4.510

Review 2.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 3.  Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management.

Authors:  Priti Tagde; Agnieszka Najda; Kalpana Nagpal; Giriraj T Kulkarni; Muddaser Shah; Obaid Ullah; Sebastian Balant; Md Habibur Rahman
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

Review 4.  Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment.

Authors:  Haiqin Liao; Chengcheng Niu
Journal:  Front Bioeng Biotechnol       Date:  2022-04-26

Review 5.  Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms.

Authors:  Neha Kaushik; Shweta B Borkar; Sondavid K Nandanwar; Pritam Kumar Panda; Eun Ha Choi; Nagendra Kumar Kaushik
Journal:  J Nanobiotechnology       Date:  2022-03-24       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.